MGL-3196
- Generic Name
- MGL-3196
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H12Cl2N6O4
- CAS Number
- 920509-32-6
- Unique Ingredient Identifier
- RE0V0T1ES0
- Background
MGL-3196 has been used in trials studying the treatment of Non-alcoholic steatohepatitis and Heterozygous Familial Hypercholesterolemia.
- Associated Conditions
- -
- Associated Therapies
- -
Drug Interaction Study of MGL-3196 With Clopidogrel
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2020-12-28
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04671069
- Locations
- ๐บ๐ธ
Celerion, Tempe, Arizona, United States
Drug Interaction Study of MGL-3196 With Pioglitazone
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04671056
- Locations
- ๐บ๐ธ
Celerion, Lincoln, Nebraska, United States
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT04643795
- Locations
- ๐บ๐ธ
Madrigal Research Center, San Antonio, Texas, United States
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 1759
- Registration Number
- NCT03900429
- Locations
- ๐จ๐ฆ
Toronto Liver Center, Toronto, Ontario, Canada
๐บ๐ธFlorida Research Institute, Lakewood Ranch, Florida, United States
๐บ๐ธGI Specialists of Georgia, Marietta, Georgia, United States
Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03220165
- Locations
- ๐บ๐ธ
Worldwide Clinical Trials Early Phase Services, LLC, San Antonio, Texas, United States
Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
- Conditions
- Interventions
- First Posted Date
- 2017-01-31
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT03038022
- Locations
- ๐ฉ๐ฐ
Madrigal Research Site, Viborg, Denmark
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT02912260
- Locations
- ๐บ๐ธ
Madrigal Research Site, Seattle, Washington, United States
Drug Interaction Study of MGL-3196 With Atorvastatin
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2016-08-30
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02749578
- Locations
- ๐บ๐ธ
Celerion, Tempe, Arizona, United States
Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT02542969
- Locations
- ๐บ๐ธ
Celerion, Tempe, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.